Lead Investigator: Mehmet Fatih Ozbay, Kirsehir Training and Research Hospital
Title of Proposal Research: Exploring the Correlation between Programmed Death-Ligand 1 (PD-L1) Levels and Eosinophilia in Advanced Lung Cancer Patients Treated with Atezolizumab
Vivli Data Request: 10106
Funding Source: None
Potential Conflicts of Interest: None
Summary of the Proposed Research:
Lung cancer, a type of cancer that originates in the lungs, is the leading cause of cancer-related deaths worldwide, affecting millions. It is often diagnosed at an advanced stage, making treatment challenging.
Recent studies have identified a correlation between the use of immune checkpoint inhibitors (ICIs), which are drugs that help the immune system recognize and attack cancer cells, and eosinophilia, an increase in a type of white blood cell called eosinophils (which can indicate an immune response) in cancer patients. This immune response may show how ICIs work, which could be important for patient outcomes. My preliminary research has aligned with these findings, showing similar correlations in patients treated with Atezolizumab.
Programmed Death-Ligand 1 (PD-L1) is protein on the surface of cells that helps them avoid being attacked by the immune system. High levels can indicate better responses to certain cancer treatments. Atezolizumab is an immunotherapy drug that helps the body’s immune system fight cancer by blocking PD-L1, allowing the immune system to target and destroy cancer cells more effectively.
This study will analyze data from patients with non-small cell lung cancer (NSCLC) treated with atezolizumab. By examining PD-L1 levels and eosinophil counts, we aim to understand how these factors influence treatment response and survival. The study is retrospective, meaning we will look at existing patient records to gather data.
While existing literature provides insights into eosinophilia associated with ICI therapy, there is a notable gap regarding the direct relationship between eosinophil counts and PD-L1 expression levels. This project aims to investigate whether PD-L1 levels can predict eosinophilic responses and potentially influence treatment efficacy and prognosis in advanced lung cancer.
Addressing this gap will not only enhance our understanding of the immunological landscape in lung cancer treatment but also refine patient management strategies. By analyzing data from a larger cohort through Vivli, this study hopes to validate the preliminary observations and explore new avenues for personalized treatment protocols.
Requested Studies:
A Phase III, Open-Label, Randomized Study of Atezolizumab (MPDL3280A, Anti-Pd-L1 Antibody) in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Patients Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer
Data Contributor: Roche
Study ID: NCT02657434
Sponsor ID: GO29438